

Target Product Profile

Indication	Protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses
Target Population	From six weeks with no upper age limit. High risk populations including pregnant women, children with underlying medical conditions and the elderly
Efficacy	Protection of at least 70% against moderate to severe disease caused by all strains of influenza A and B across all age groups
Duration of protection	Three to five years
Onset of immunity	Four weeks
Herd protection	Desirable
Dosing schedule	Vaccine naïve subjects (pediatric): No more than 3 doses over a 5 year period, compatible with current EPI schedule including co-administration Influenza primed subjects: Single or two dose primary series, booster every five years Single or two doses in Pregnant women
Vaccine Safety	No worse than EPI vaccines
Stability/ Shelf life	Minimum shelf life of 2 years at 2-8 deg C
Product registration path	Universal flu vaccine is likely to be licensed as Seasonal flu vaccine also useful for pandemic, based on clinical efficacy against circulating influenza strains with passive serum transfer studies in appropriate animal model (ferrets?) showing protection against pandemic strains
WHO PQ date	2027
Primary target delivery channel	Routine immunization for infants/children Pre-pandemic global campaign
Target countries	All
Dosing schedule	Vaccine naïve subjects (pediatric): No more than 3 doses over a 5 year period, compatible with current EPI schedule including co-administration Influenza primed subjects: Single or two dose primary series, booster every five years